Engineering topics

Goncalves, Andre R.

Publications and source records attributed to Goncalves, Andre R..

3 records

DOE OSTI2024

Computationally restoring the potency of a clinical antibody against Omicron

The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab. Cilgavimab, like its progenitor COV2-2130, is a class 3 antibody that is compatible with other antibodies in combination4 and is challenging to replace with existing approaches. Rapidly modifying such high-value antibodies to restore efficacy against emerging variants is a compelling mitigation strategy. We sought to redesign and renew the efficacy of COV2-2130 against Omicron BA.1 and BA.1.1 strains while maintaining efficacy against the dominant Delta variant. Here we show that our computationally redesigned antibody, 2130-1-0114-112, achieves this objective, simultaneously increases neutralization potency against Delta and subsequent variants of concern, and provides protection in vivo against the strains tested: WA1/2020, BA.1.1 and BA.5. Deep mutational scanning of tens of thousands of pseudovirus variants reveals that 2130-1-0114-112 improves broad potency without increasing escape liabilities. Our results suggest that computational approaches can optimize an antibody to target multiple escape variants, while simultaneously enriching potency. Our computational approach does not require experimental iterations or pre-existing binding data, thus enabling rapid response strategies to address escape variants or lessen escape vulnerabilities.

60 APPLIED LIFE SCIENCES↗

DOE OSTI2023

Bayesian Exploration of Phenomenological EoS of Neutron/Hybrid Stars with Recent Observations

The description of the stellar interior of compact stars remains as a big challenge for the nuclear astrophysics community. The consolidated knowledge is restricted to density regions around the saturation of hadronic matter ρ 0 =2.8 × 10 14 g cm -3 , regimes where our nuclear models are successfully applied. As one moves towards higher densities and extreme conditions up to the quark/gluons deconfinement, little can be said about the microphysics of the equation of state (EoS). Here, we employ a Markov Chain Monte Carlo (MCMC) strategy to access the variability at high density regions of polytropic piecewise models for neutron star (NS) EoS or possible hybrid stars, i.e., a NS with a small quark-matter core. With a fixed description of the hadronic matter for low density, below the nuclear saturation density, we explore a variety of models for the high density regimes leading to stellar masses near to 2.5 M ⊙ , in accordance with the observations of massive pulsars. The models are constrained, including the observation of the merger of neutrons stars from VIRGO-LIGO and with the pulsar observed by NICER. In addition, we also discuss the possibility of the use of a Bayesian power regression model with heteroscedastic error. The set of EoS from the Laser Interferometer Gravitational-Wave Observatory (LIGO) was used as input and treated as the data set for the testing case.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

DOE OSTI2020

Multitask Recommender Systems for Cancer Drug Response

The problem we are currently trying to address is that there are many types of cancer drugs and many types of cancers and there is not always experimental data for a specific cancer type and cancer drug interaction. While there is a large possible set of feasible drug and cancer combinations, testing each pair is not realistic due to the high monetary cost of cell-based assays. Thus, this leaves researchers with a difficult choice of what drugs they should test on specific cancer types. This issue is known as the cold-start problem. Our focus is on developing recommender systems capable of addressing the cold-start problem as it relates to interaction between cancer types and cancer drugs. One of the most effective ways to address the cold-start problem is through large data analysis, however due to the cost prohibitive nature of cancer research the largest available data set size is the Genomics of Drug Sensitivity in Cancer with 494,973 genomic associations. To achieve optimal model performance on the cold-start problem, it is advantageous to employ multitask algorithms that are capable of transferring information between cancer datasets. The aim of this report is to draw from adaptations and state of the art developments in both algorithms for recommender systems and multitask learning to model the interaction between cancer cell lines and cancer drugs. Cancer cell lines are defined by the US National Cancer Institute as "cancer cells that keep dividing and growing over time, under certain conditions in a laboratory". This paper will focus on evaluating the performance of Neural Collaborative Filtering and Gaussian Processes, as well as their multitask adaptations, on cancer datasets from CCLE, NCI60, GDSC and CTRP. These methods will be evaluated on model performance in regression prediction but also in interpretability.

60 APPLIED LIFE SCIENCES↗